Advertisement

Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials

  • Katsuhiko Nakatsukasa
  • Hiroshi Koyama
  • Yoshimi Ouchi
  • Kouichi Sakaguchi
  • Yoshifumi Fujita
  • Takayuki Matsuda
  • Makoto Kato
  • Eiichi Konishi
  • Tetsuya TaguchiEmail author
Original Article
  • 23 Downloads

Abstract

Aromatase inhibitors (AIs) are the gold standard therapy for breast cancer in postmenopausal women. AI suppresses the conversion of androgens to estrogens; however, this results in osteopenia, osteoporosis, and bone fracture, thus reducing the patient’s quality of life. The use of adjuvant denosumab reduces the risk of clinical fractures in postmenopausal patients with breast cancer receiving AI. However, the efficacy of denosumab in the treatment of AI-associated bone loss has not been prospectively evaluated in Japan. In this study, we aimed to investigate the predictive factors for the efficacy of denosumab in postmenopausal patients with breast cancer treated with AI by analyzing the results of two prospective trials. The patients received 60 mg denosumab subcutaneously every 6 months. The primary endpoint was percentage change in lumbar spine bone mineral density (BMD) from baseline to month 12 in lumbar spine. Post hoc analysis and T tests were performed. A total of 205 patients were enrolled. At 12 and 24 months, the lumbar spine BMD increased by 5.6% [95% confidence interval (CI) 4.9–6.3] and 8.3% (95% CI 7.5–9.1), respectively. Subgroup analysis was conducted according to the time of AI therapy initiation, type of AI therapy, age, time since menopause, baseline body mass index, and BMD. The results showed that baseline lumbar and left femoral BMD was significantly associated with a percentage change in these sites, respectively. In addition, baseline left femoral BMD was also associated with a change in lumbar BMD. In conclusion, the baseline BMD in the lumbar spine was a predictive indicator for the efficacy of denosumab in this site and the baseline BMD in left femoral neck was a predictive indicator in lumbar spine and left femur.

Keywords

Breast cancer Aromatase inhibitor Denosumab Predictive factor 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflicts of interest.

References

  1. 1.
    Suzuki T, Yoshida H (2010) Low bone mineral density at femoral neck is a predictor of increased mortality in elderly Japanese women. Osteoporos Int 1:71–79CrossRefGoogle Scholar
  2. 2.
    Fisher ES, Baron JA, Malenka DJ, Barrett JA, Kniffin WD, Whaley FS, Bubolz TA (1991) Hip fracture incidence and mortality in New England. Epidemiology 2:116–122CrossRefGoogle Scholar
  3. 3.
    Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE (1989) Survival experience of aged hip fracture patients. Am J Public Health 79:274–278CrossRefGoogle Scholar
  4. 4.
    Pitto RP (1994) The mortality and social prognosis of hip fractures. A prospective multifactorial study. Int Orthop 18:109–113CrossRefGoogle Scholar
  5. 5.
    Muraki S, Yamamoto S, Ishibashi H, Nakamura K (2006) Factors associated with mortality following hip fracture in Japan. J Bone Miner Metab 24:100–104CrossRefGoogle Scholar
  6. 6.
    Johansson C, Black D, Jonell O, Oden A, Mellstrom D (1998) Bone mineral density is a predictor of survival. Calcif Tissue Int 63:190–196CrossRefGoogle Scholar
  7. 7.
    Kado DM, Browner WS, Palemo L, Nevitt MC, Genant HK, Cummings SR (1999) Vertebral fractures and mortality in older women. Arch Int Med 159:1215–1220CrossRefGoogle Scholar
  8. 8.
    Ensruud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochoberg MC, Santora AC, Black DM (2000) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriat Soc 48:241–249CrossRefGoogle Scholar
  9. 9.
    Trivedi DP, Khaw KT (2001) Bone mineral density at the hip predicts mortality in elderly men. Osteoporos Int 12:259–265CrossRefGoogle Scholar
  10. 10.
    Nguyen ND, Center JR, Eisman JA, Nguyen TV (2007) Bone loss, weight loss, and weight fluctuation predict mortality risk in elderly men and women. J Bone Miner Res 22:1147–1154CrossRefGoogle Scholar
  11. 11.
    Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML et al (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1–12CrossRefGoogle Scholar
  12. 12.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T (2017) Effect of denosumab administration on low bone mineral density (T-score − 1.0 to − 2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Bone Miner Metab.  https://doi.org/10.1007/s00774-017-0884-x (Epub ahead of print) Google Scholar
  13. 13.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T (2018) Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab.  https://doi.org/10.1007/s00774-018-0917-0 (Epub ahead of print) Google Scholar
  14. 14.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T (2018) Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study. Ther Clin Risk Manag 14:1213–1218CrossRefGoogle Scholar
  15. 15.
    Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K et al (2018) The effect of denosumab on low bone mineral density (T-score − 1.0 to − 2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results. Breast Cancer.  https://doi.org/10.1007/s12282-018-0896-y (Epub ahead of print) Google Scholar
  16. 16.
    Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet 386:433–443CrossRefGoogle Scholar
  17. 17.
    Ellis GK, Bone HG, Chlebowski R, Paul D, Spadfora S, Smith J, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875–4882CrossRefGoogle Scholar
  18. 18.
    Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S, Bogado CE, Bilezikian JP, Seeman E (2014) Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 59:173–179CrossRefGoogle Scholar
  19. 19.
    Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS (2011) Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49:151–161CrossRefGoogle Scholar
  20. 20.
    Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN et al (1996) Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141–150CrossRefGoogle Scholar
  21. 21.
    Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC II (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488–501CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Katsuhiko Nakatsukasa
    • 1
  • Hiroshi Koyama
    • 2
  • Yoshimi Ouchi
    • 1
  • Kouichi Sakaguchi
    • 1
  • Yoshifumi Fujita
    • 1
  • Takayuki Matsuda
    • 3
  • Makoto Kato
    • 4
  • Eiichi Konishi
    • 5
  • Tetsuya Taguchi
    • 1
    Email author
  1. 1.Department of Endocrine and Breast SurgeryKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Nara City HospitalNaraJapan
  3. 3.Saiseikai Kyoto HospitalKyotoJapan
  4. 4.Kato Breast Surgery ClinicKusatsu, ShigaJapan
  5. 5.Department of Surgical PathologyKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations